Segment information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment information

11. Segment information

The Company operates and manages its business as one reportable and operating segment dedicated to biopharmaceutical research and development company specializing in oncology. The measure of segment assets is reported on the balance sheet as total assets.

The Company’s CODM reviews financial information and decides how to allocate resources based on net income (loss).

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

	Year ended December 31,
	2024			2023
Revenue	$	-		$	-
Less:
Research and development		(772,702	)		(279,489	)
Payroll and related		(1,093,327	)		(1,174,239	)
Insurance		(209,922	)		(674,976	)
Professional fees primarily related to intellectual property		(895,682	)		(963,926	)
Operating expenses		(651,509	)		(730,996	)
Sale of royalty and milestone rights, net of transaction costs		2,000,000			4,167,219
Other income		33,456			56,850
Net income (loss)	$	(1,589,686	)	$	400,443